Bristol Myers Squibb Stock Total Asset

BMY Stock

USD 56.29 0.09 0.16%

Bristol Myers Squibb fundamentals help investors to digest information that contributes to Bristol Myers' financial success or failures. It also enables traders to predict the movement of Bristol Stock. The fundamental analysis module provides a way to measure Bristol Myers' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Bristol Myers stock.

	Last Reported	Projected for Next Year
Total Assets	109.4 B	114.9 B
Intangibles To Total Assets	0.46	0.48

Total Assets is likely to rise to about 114.9 B in 2025. Intangibles To Total Assets is likely to rise to 0.48 in 2025.

This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools.

Bristol Myers Squibb Company Total Asset Analysis

Bristol Myers' Total Asset is everything that a business owns. It is the sum of current and long-term assets owned by a firm at a given time. These assets are listed on a balance sheet and typically valued based on their purchasing prices, not the current market value.

Total Asset

Tangible Assets

+

Intangible Assets

More About Total Asset | All Equity Analysis

Current Bristol Myers Total Asset

95.16 B

Most of Bristol Myers' fundamental indicators, such as Total Asset, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Bristol Myers Squibb is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.

Bristol Total Asset Driver Correlations

Understanding the fundamental principles of building solid financial models for Bristol Myers is extremely important. It helps to project a fair market value of Bristol Stock properly, considering its historical fundamentals such as Total Asset. Since Bristol Myers' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Bristol Myers' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Bristol Myers' interrelated accounts and indicators.

	Total Assets	Total Stockholder Equity	Net Debt	Retained Earnings	Net Receivables	Good Will	Total Liab	Total Current Assets	Short Term Debt	Intangible Assets	Accounts Payable	Short Term Investments	Capital Stock	Common Stock	Long Term Debt	Treasury Stock	Property Plant Equipment	Current Deferred Revenue	Net Tangible Assets	Total Permanent Equity	Long Term Debt Total	Capital Surpluse	Deferred Long Term Liab	Long Term Investments	Short Long Term Debt	Cash And Equivalents	Net Invested Capital	Net Working Capital
Total Assets		0.97	0.98	-0.04	0.79	0.97	0.99	0.95	0.86	0.95	0.74	0.12	0.9	0.9	0.98	-0.8	0.85	0.33	-0.97	0.41	0.98	0.96	0.74	-0.51	-0.38	0.91	0.97	0.87
Total Stockholder Equity	0.97		0.93	0.07	0.69	0.92	0.94	0.87	0.83	0.97	0.66	0.28	0.84	0.84	0.94	-0.71	0.81	0.39	-0.93	0.39	0.94	0.89	0.78	-0.55	-0.4	0.9	0.96	0.87
Net Debt	0.98	0.93		-0.12	0.84	0.98	0.99	0.94	0.9	0.93	0.73	0.0	0.92	0.92	0.99	-0.85	0.89	0.3	-0.98	0.47	0.99	0.98	0.71	-0.55	-0.41	0.91	0.98	0.86
Retained Earnings	-0.04	0.07	-0.12		-0.04	0.01	-0.07	-0.01	-0.12	-0.11	0.28	0.4	-0.06	-0.06	-0.12	-0.03	0.02	-0.54	0.15	-0.41	-0.18	-0.19	-0.06	0.4	-0.16	-0.17	-0.13	-0.09
Net Receivables	0.79	0.69	0.84	-0.04		0.9	0.83	0.89	0.87	0.61	0.83	-0.11	0.8	0.8	0.83	-0.96	0.84	-0.15	-0.74	0.54	0.8	0.89	0.28	-0.37	-0.52	0.69	0.75	0.67
Good Will	0.97	0.92	0.98	0.01	0.9		0.98	0.96	0.91	0.88	0.82	0.04	0.9	0.9	0.98	-0.9	0.9	0.15	-0.93	0.44	0.96	0.98	0.63	-0.47	-0.45	0.87	0.94	0.84
Total Liab	0.99	0.94	0.99	-0.07	0.83	0.98		0.96	0.88	0.93	0.77	0.06	0.91	0.91	0.99	-0.84	0.87	0.29	-0.97	0.43	0.99	0.97	0.71	-0.52	-0.4	0.91	0.97	0.87
Total Current Assets	0.95	0.87	0.94	-0.01	0.89	0.96	0.96		0.86	0.81	0.87	0.08	0.87	0.87	0.94	-0.88	0.83	0.11	-0.87	0.41	0.93	0.95	0.54	-0.42	-0.4	0.83	0.89	0.83
Short Term Debt	0.86	0.83	0.9	-0.12	0.87	0.91	0.88	0.86		0.82	0.68	0.06	0.86	0.86	0.89	-0.86	0.88	0.24	-0.88	0.58	0.88	0.92	0.57	-0.5	-0.46	0.86	0.88	0.77
Intangible Assets	0.95	0.97	0.93	-0.11	0.61	0.88	0.93	0.81	0.82		0.55	0.17	0.84	0.84	0.94	-0.65	0.8	0.55	-0.97	0.42	0.95	0.89	0.87	-0.64	-0.35	0.93	0.97	0.86
Accounts Payable	0.74	0.66	0.73	0.28	0.83	0.82	0.77	0.87	0.68	0.55		0.05	0.67	0.67	0.73	-0.85	0.69	-0.31	-0.64	0.1	0.69	0.75	0.32	-0.12	-0.28	0.57	0.63	0.58
Short Term Investments	0.12	0.28	0.0	0.4	-0.11	0.04	0.06	0.08	0.06	0.17	0.05		-0.07	-0.07	0.05	0.17	-0.1	0.17	-0.02	-0.14	0.03	-0.04	0.25	0.09	-0.06	0.2	0.1	0.27
Capital Stock	0.9	0.84	0.92	-0.06	0.8	0.9	0.91	0.87	0.86	0.84	0.67	-0.07		1.0	0.91	-0.84	0.95	0.27	-0.91	0.48	0.91	0.92	0.62	-0.54	-0.39	0.85	0.93	0.84
Common Stock	0.9	0.84	0.92	-0.06	0.8	0.9	0.91	0.87	0.86	0.84	0.67	-0.07	1.0		0.91	-0.84	0.95	0.27	-0.91	0.48	0.91	0.92	0.62	-0.54	-0.39	0.85	0.93	0.84
Long Term Debt	0.98	0.94	0.99	-0.12	0.83	0.98	0.99	0.94	0.89	0.94	0.73	0.05	0.91	0.91		-0.83	0.87	0.32	-0.97	0.48	1.0	0.98	0.71	-0.58	-0.43	0.94	0.98	0.89
Treasury Stock	-0.8	-0.71	-0.85	-0.03	-0.96	-0.9	-0.84	-0.88	-0.86	-0.65	-0.85	0.17	-0.84	-0.84	-0.83		-0.87	0.14	0.79	-0.41	-0.81	-0.89	-0.35	0.34	0.43	-0.68	-0.77	-0.65
Property Plant Equipment	0.85	0.81	0.89	0.02	0.84	0.9	0.87	0.83	0.88	0.8	0.69	-0.1	0.95	0.95	0.87	-0.87		0.14	-0.87	0.55	0.86	0.9	0.62	-0.57	-0.5	0.79	0.88	0.79
Current Deferred Revenue	0.33	0.39	0.3	-0.54	-0.15	0.15	0.29	0.11	0.24	0.55	-0.31	0.17	0.27	0.27	0.32	0.14	0.14		-0.42	0.26	0.38	0.26	0.63	-0.47	0.13	0.48	0.45	0.41
Net Tangible Assets	-0.97	-0.93	-0.98	0.15	-0.74	-0.93	-0.97	-0.87	-0.88	-0.97	-0.64	-0.02	-0.91	-0.91	-0.97	0.79	-0.87	-0.42		-0.45	-0.98	-0.95	-0.81	0.61	0.38	-0.94	-0.98	-0.87
Total Permanent Equity	0.41	0.39	0.47	-0.41	0.54	0.44	0.43	0.41	0.58	0.42	0.1	-0.14	0.48	0.48	0.48	-0.41	0.55	0.26	-0.45		0.5	0.53	0.17	-0.76	-0.77	0.52	0.5	0.47
Long Term Debt Total	0.98	0.94	0.99	-0.18	0.8	0.96	0.99	0.93	0.88	0.95	0.69	0.03	0.91	0.91	1.0	-0.81	0.86	0.38	-0.98	0.5		0.98	0.72	-0.61	-0.41	0.94	0.99	0.89
Capital Surpluse	0.96	0.89	0.98	-0.19	0.89	0.98	0.97	0.95	0.92	0.89	0.75	-0.04	0.92	0.92	0.98	-0.89	0.9	0.26	-0.95	0.53	0.98		0.62	-0.57	-0.41	0.89	0.96	0.85
Deferred Long Term Liab	0.74	0.78	0.71	-0.06	0.28	0.63	0.71	0.54	0.57	0.87	0.32	0.25	0.62	0.62	0.71	-0.35	0.62	0.63	-0.81	0.17	0.72	0.62		-0.5	-0.11	0.76	0.77	0.73
Long Term Investments	-0.51	-0.55	-0.55	0.4	-0.37	-0.47	-0.52	-0.42	-0.5	-0.64	-0.12	0.09	-0.54	-0.54	-0.58	0.34	-0.57	-0.47	0.61	-0.76	-0.61	-0.57	-0.5		0.56	-0.66	-0.64	-0.6
Short Long Term Debt	-0.38	-0.4	-0.41	-0.16	-0.52	-0.45	-0.4	-0.4	-0.46	-0.35	-0.28	-0.06	-0.39	-0.39	-0.43	0.43	-0.5	0.13	0.38	-0.77	-0.41	-0.41	-0.11	0.56		-0.47	-0.41	-0.42
Cash And Equivalents	0.91	0.9	0.91	-0.17	0.69	0.87	0.91	0.83	0.86	0.93	0.57	0.2	0.85	0.85	0.94	-0.68	0.79	0.48	-0.94	0.52	0.94	0.89	0.76	-0.66	-0.47		0.95	0.93
Net Invested Capital	0.97	0.96	0.98	-0.13	0.75	0.94	0.97	0.89	0.88	0.97	0.63	0.1	0.93	0.93	0.98	-0.77	0.88	0.45	-0.98	0.5	0.99	0.96	0.77	-0.64	-0.41	0.95		0.9
Net Working Capital	0.87	0.87	0.86	-0.09	0.67	0.84	0.87	0.83	0.77	0.86	0.58	0.27	0.84	0.84	0.89	-0.65	0.79	0.41	-0.87	0.47	0.89	0.85	0.73	-0.6	-0.42	0.93	0.9

Click cells to compare fundamentals

Bristol Total Asset Historical Pattern

Today, most investors in Bristol Myers Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Bristol Myers' growth ratios. Consistent increases or drops in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's total asset growth rates may not be enough to decide which company is a better investment. That's why investors frequently use a static breakdown of Bristol Myers total asset as a starting point in their analysis.

Bristol Myers Total Asset

Timeline

Total Asset is typically divided on the balance sheet on current asset and long-term asset. Long-term is the value of company property and other capital assets that are expected to be useable for more than one year. Long term assets are reported net of depreciation. On the other hand current assets are assets that are expected to be sold or converted to cash as part of normal business operation.

Competition

Predict Bristol Myers

Total Assets Over Time

Bristol Total Assets

Total Assets

114.9 Billion

At this time, Bristol Myers' Total Assets are fairly stable compared to the past year.

Based on the latest financial disclosure, Bristol Myers Squibb has a Total Asset of 95.16 B. This is much higher than that of the Pharmaceuticals sector and significantly higher than that of the Health Care industry. The total asset for all United States stocks is significantly lower than that of the firm.

Bristol Total Asset Peer Comparison

Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Bristol Myers' direct or indirect competition against its Total Asset to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Bristol Myers could also be used in its relative valuation, which is a method of valuing Bristol Myers by comparing valuation metrics of similar companies.

Bristol Myers is currently under evaluation in total asset category among its peers.

Bristol Myers ESG Sustainability

Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Bristol Myers' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Bristol Myers' managers, analysts, and investors.

Environmental

Governance

Social

Bristol Myers Institutional Holders

Institutional Holdings refers to the ownership stake in Bristol Myers that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Bristol Myers' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Bristol Myers' value.

		Shares
Bank Of New York Mellon Corp	2024-09-30	23.3 M
Northern Trust Corp	2024-09-30	21.2 M
T. Rowe Price Associates, Inc.	2024-09-30	20.2 M
Ameriprise Financial Inc	2024-09-30	20.1 M
Legal & General Group Plc	2024-09-30	20 M
Ubs Asset Mgmt Americas Inc	2024-09-30	19.1 M
Bank Of America Corp	2024-09-30	18.1 M
Amvescap Plc.	2024-09-30	16.2 M
Dodge & Cox	2024-09-30	15.6 M
Vanguard Group Inc	2024-09-30	188.6 M
Blackrock Inc	2024-09-30	159.7 M

Bristol Fundamentals

	Return On Equity	-0.31
	Return On Asset	0.0607
	Profit Margin	(0.15) %
	Operating Margin	0.18 %
	Current Valuation	156.7 B
	Shares Outstanding	2.03 B
	Shares Owned By Insiders	0.11 %
	Shares Owned By Institutions	78.54 %
	Number Of Shares Shorted	24.93 M
	Price To Earning	24.88 X
	Price To Book	6.62 X
	Price To Sales	2.41 X
	Revenue	45.01 B
	Gross Profit	35.99 B
	EBITDA	19.42 B
	Net Income	8.04 B
	Cash And Equivalents	9.12 B
	Cash Per Share	6.21 X
	Total Debt	41.46 B
	Debt To Equity	1.32 %
	Current Ratio	1.42 X
	Book Value Per Share	8.45 X
	Cash Flow From Operations	13.86 B
	Short Ratio	2.24 X
	Earnings Per Share	(3.61) X
	Price To Earnings To Growth	1.92 X
	Target Price	61.01
	Number Of Employees	34.1 K
	Beta	0.44
	Market Capitalization	114.35 B
	Total Asset	95.16 B
	Retained Earnings	28.77 B
	Working Capital	9.51 B
	Current Asset	10.41 B
	Current Liabilities	8.02 B
	Annual Yield	0.04 %
	Five Year Return	2.96 %
	Net Asset	95.16 B
	Last Dividend Paid	2.4

About Bristol Myers Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze Bristol Myers Squibb's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Bristol Myers using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Bristol Myers Squibb based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Please read more on our fundamental analysis page.

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

BTC	Bitcoin
TRX	TRON
BNB	Binance Coin

Additional Tools for Bristol Stock Analysis

When running Bristol Myers' price analysis, check to measure Bristol Myers' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Bristol Myers is operating at the current time. Most of Bristol Myers' value examination focuses on studying past and present price action to predict the probability of Bristol Myers' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Bristol Myers' price. Additionally, you may evaluate how the addition of Bristol Myers to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC